Document:

Exhibit

EXHIBIT 10.1 

EXECUTION COPY

EIGHTH AMENDMENT TO CREDIT AGREEMENT 
AND LIMITED WAIVER
This EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER (this “Amendment”), is made and entered into as of October 20, 2016 (the “Eighth Amendment Closing Date”), among NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C., a Delaware limited liability company (the “Borrower”), the other Credit Parties party hereto, the financial institutions party hereto from time to time (collectively, the “Lenders” and individually each a “Lender”), and HEALTHCARE FINANCIAL SOLUTIONS, LLC, a Delaware limited liability company (as the successor in interest to GENERAL ELECTRIC CAPITAL CORPORATION), as administrative agent for the Secured Parties (in such capacity, the “Agent”), and as a Lender, and Swingline Lender. 
W I T N E S S E T H:
WHEREAS, the Borrower, the other Credit Parties party thereto, the Lenders party thereto and Agent are parties to that certain Credit Agreement, dated as of March 31, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), pursuant to which the Lenders committed to make certain loans and other financial accommodations to the Borrower upon the terms and conditions set forth therein; 
WHEREAS, pursuant to Section 4.5(a) of that certain Seventh Amendment to Credit Agreement dated as of August 19, 2016 (the “Seventh Amendment”), among the Borrower, the other Credit Parties party thereto, the Lenders party thereto, and Agent, the Credit Parties were required to have delivered, on or prior to October 3, 2016, evidence in form and substance satisfactory to Agent of the termination of the UCC financing statement with file no. 2016-000-6161-0, naming Perimeter Road Surgical Hospital, LLC (“Perimeter Road”), as debtor, filed with the Arizona Secretary of State on February 10, 2016 in favor of Cardinal Health (the “Perimeter Road Financing Statement”);
WHEREAS, a Default or an Event of Default, as applicable, has occurred pursuant to Section 3.23(a) and Section 5.12(b) of the Credit Agreement due to Parent being a lessee under the leases set forth on Schedule 3.9 of the Credit Agreement as of the Seventh Amendment Effective Date (the “Lease Default”);
WHEREAS, a Default or an Event of Default, as applicable, has occurred pursuant to Section 3.23(a) and Section 5.12(b) of the Credit Agreement due to Parent owning the Trademarks set forth on Schedule 5 of the Guaranty and Security Agreement as of the Seventh Amendment Effective Date (the “Trademarks Default”);
WHEREAS, a Default or an Event of Default, as applicable, has occurred pursuant to Section 7.1(d) of the Credit Agreement due to the Credit Parties’ failure to deliver evidence in form and substance satisfactory to Agent of the termination of the Perimeter Road Financing Statement on or prior to October 3, 2016 (the “Perimeter Road Financing Statement Default”);
WHEREAS, pursuant to Section 5.7 of the Credit Agreement, the Credit Parties are prohibited from paying any management, consulting or similar fees to any Affiliate of any Credit Party, subject to certain exceptions (the “Management Fees Prohibition”);
WHEREAS, an Event of Default has occurred and is continuing under Section 7.1(c) of the Credit Agreement due to the Credit Parties’ failure to comply with the Management Fees Prohibition (the “Management Fees Prohibition Default” and together with the Perimeter Road Financing Statement Default, the Lease Default and the Trademarks Default, the “Specified Events of Default”); 

82932789_5

WHEREAS, the Borrower and the other Credit Parties have requested that Agent and the Lenders (a) amend the Credit Agreement to permit Cardinal Health’s Lien on the assets of Perimeter Road in an aggregate principal amount not to exceed $25,000 at any time, (b) amend the Management Fees Prohibition and (c) waive the Specified Events of Default; and
WHEREAS, Agent and the Lenders are willing to amend certain provisions of the Credit Agreement, all subject to and in accordance with the terms and conditions specified herein.
NOW, THEREFORE, in consideration of the foregoing, and the respective agreements, warranties and covenants contained herein, the parties hereto agree, covenant, and warrant as follows:
SECTION 1.  DEFINITIONS.
1.1    Interpretation.  All capitalized terms used herein (including the recitals hereto) shall have the respective meanings assigned thereto in the Credit Agreement unless otherwise defined herein.
SECTION 2.  AMENDMENTS. 
Subject to the terms and conditions of this Amendment, including, without limitation, the representations, warranties, and covenants in Section 4 hereof and the conditions precedent to the effectiveness of this Amendment in Section 5 hereof:
2.1    Section 3.23.  Effective as of the Eighth Amendment Closing Date, Section 3.23(a) of the Credit Agreement is hereby amended and restated in its entirety as follows:
“(b)    Parent has not engaged in any business activities and does not own any Property other than (i) ownership of the Stock and Stock Equivalents of Holdings, (ii) activities and contractual rights incidental to maintenance of its corporate existence, (iii) performance of its obligations under the Loan Documents to which it is a party, (iv) being a lessee under the leases set forth on Schedule 3.9 of the Credit Agreement as of the Seventh Amendment Effective Date and (v) the Trademarks set forth on Schedule 5 of the Guaranty and Security Agreement as of the Seventh Amendment Effective Date.”

2.2    Section 5.1.  Effective as of the Eighth Amendment Closing Date, Section 5.1 of the Credit Agreement is hereby amended by deleting the word “and” at the end of Section 5.1(o), replacing the period at the end of Section 5.1(p) with “; and”, and adding the following new clause (q) to the end:
“(q)    Liens on the assets of Perimeter Road Surgical Hospital, LLC in favor of Cardinal Health securing Indebtedness in an aggregate outstanding amount not to exceed $25,000 at any time.”
2.3    Section 5.7.  Effective as of the Eighth Amendment Closing Date, Section 5.7 of the Credit Agreement is hereby amended and restated in its entirety as follows:
“5.7    Management Fees and Compensation.    No Credit Party shall, and no Credit Party shall permit any of its Subsidiaries to, pay any management, consulting or similar fees to any Affiliate of any Credit Party or to any officer, director or employee of any Credit Party except:
(a)    payment of reasonable compensation to officers and employees for actual services rendered to the Credit Parties and their Subsidiaries in the Ordinary Course of Business;

-2-
82932789_5

(b)    payment of directors’ fees (excluding compensation in the form of the Parent’s Stock or Stock Equivalents) and reimbursement of actual out-of-pocket expenses incurred in connection with attending board of director meetings not to exceed in the aggregate, with respect to all such items, $500,000 in any Fiscal Year of the Borrower;

(c)    payment of fees to Borrower pursuant to the Marketing Services Agreements; and

(d)    subject to Section 5.6, payment of fees to Borrower and any Credit Party that is a Wholly-Owned Subsidiary of Borrower.”
2.4    Section 5.12.  Effective as of the Eighth Amendment Closing Date, Section 5.12(b) of the Credit Agreement is hereby amended and restated in its entirety as follows:
“(b)    Parent shall not engage in any business activities or own any Property other than (i) ownership of the Stock and Stock Equivalents of Holdings, (ii) activities and contractual rights incidental to maintenance of its corporate existence, (iii) being a lessee under the leases set forth on Schedule 3.9 of the Credit Agreement as of the Seventh Amendment Effective Date and (iv) the Trademarks set forth on Schedule 5 of the Guaranty and Security Agreement as of the Seventh Amendment Effective Date.”

2.5    Schedule 5.1.  The information set forth in Annex 1 hereby amends and restates in its entirety the information set forth in Schedule 5.1 of the Credit Agreement.  By acknowledging and agreeing to this Amendment, each of the undersigned hereby agrees that the information set forth in Annex 1 may be attached to the Credit Agreement.

SECTION 3.  ACKNOWLEDGMENTS
3.1    Acknowledgment of Obligations.  All Obligations, together with interest accrued and accruing thereon, and fees, costs, expenses and other charges now or hereafter payable by the Credit Parties to the Lenders, are unconditionally owing by the Credit Parties, all without offset, defense or counterclaim of any kind, nature or description whatsoever.
3.2    Acknowledgment of Liens.  Each of the Credit Parties hereby acknowledges, confirms and agrees that Agent on behalf of the Lenders has and shall continue to have valid, enforceable and perfected first priority Liens (subject to certain Permitted Liens) upon and security interests in the Collateral heretofore granted by the Credit Parties to Agent on behalf of the Lenders pursuant to the Loan Documents.
3.3    Binding Effect of Documents.  Each of the Credit Parties hereby acknowledges, confirms and agrees that: (a) each of the Loan Documents to which it is a party has been duly executed and delivered to Agent, and each is in full force and effect as of the date hereof, (b) the agreements and obligations of each Credit Party contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of such Credit Party, enforceable against it in accordance with their respective terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally or by equitable principles relating to enforceability, and no Credit Party has a valid defense to the enforcement of such obligations and (c) Agent and the Lenders are and shall be entitled to the rights, remedies and benefits provided for them in the Loan Documents and applicable law.
SECTION 4.  REPRESENTATIONS, WARRANTIES AND COVENANTS

-3-
82932789_5

Borrower and each of the other Credit Parties hereby further represent, warrant, and covenant with and to Agent and the Lenders as follows:
4.1    Representations and Warranties.  After giving effect to this Amendment, each of the representations and warranties made by or on behalf of the Credit Parties to Agent and the Lenders in all of the Loan Documents was true and correct in all material respects when made and is true and correct in all material respects on and as of the date of this Amendment with the same full force and effect as if each of such representations and warranties had been made by such Person on the date hereof and in this Amendment, except to the extent that such representation and warranty expressly relates to an earlier date and except for changes therein expressly permitted or expressly contemplated by the Credit Agreement, and except as consented to or waived.
4.2    Binding Effect of Documents.  This Amendment and the other Loan Documents have been duly executed and delivered to Agent and the Lenders by the Borrower and each of the other Credit Parties and are in full force and effect, as modified hereby.
4.3    No Conflict, Etc.  The execution and delivery and performance of this Amendment by the Borrower and each of the other Credit Parties will not violate any federal, state or any other material law, rule, regulation or order or material contractual obligation of such Person in any material respect and will not result in, or require, the creation or imposition of any Lien (other than the Liens created by the Collateral Documents or any Permitted Liens) on any of its Properties or revenues.
4.4    Events of Default.  No Events of Default, other than the Specified Events of Default, as waived in Section 6 of this Amendment, are continuing as of the date hereof.  The parties hereto acknowledge, confirm, and agree that any material misrepresentation by any Credit Party or any failure of any Credit Party to comply with the covenants, conditions and agreements contained in this Amendment shall constitute an Event of Default under the Credit Agreement.
SECTION 5.  CONDITIONS TO EFFECTIVENESS 
The effectiveness of the terms and provisions of this Amendment shall be subject to each of the following conditions precedent having been satisfied as determined in Agent’s sole discretion prior to the Eighth Amendment Closing Date:
(a)    Agent shall have received one or more counterparts of this Amendment, duly executed and delivered by the Credit Parties and the Lenders; and
(b)    All reasonable out-of-pocket costs and expenses referenced in Section 9.5 of the Credit Agreement that have been invoiced to the Borrower shall have been paid or reimbursed by the Borrower, including, without limitation, those relating to this Amendment.
SECTION 6.  LIMITED WAIVER
In reliance upon the representations, warranties and covenants of the Borrower and each other Credit Party contained herein, and subject to the terms and conditions of this Amendment, including without limitation the fulfillment of the conditions to effectiveness specified in Section 5 above, the Agent and the undersigned Lenders hereby waive the Specified Events of Default, such waiver to be effective as of October 3, 2016. The aforesaid waiver relates solely to the Specified Events of Default and nothing in this Amendment is intended or shall be construed to be a waiver by Agent or any Lender of any other Default or Event of Default which may currently exist or hereafter occur. 

-4-
82932789_5

SECTION 7.  ADDITIONAL COVENANTS AND PROVISIONS OF GENERAL APPLICATION
7.1    Effect of this Amendment.  Except for the amendments expressly set forth and referred to in Section 2, no other changes or modifications to the Loan Documents are intended or implied and in all other respects the Loan Documents are hereby specifically ratified and confirmed by all parties hereto as of the date hereof.  In the event of any conflict between the terms of this Amendment and the other Loan Documents, the terms of this Amendment shall control.  Nothing in this Amendment is intended, or shall be construed, to constitute a novation or an accord and satisfaction of any Credit Party’s Obligations under or in connection with the Credit Agreement or any of the other Loan Documents or to modify, affect or impair the perfection or continuity of Agent’s security interests in, security titles to or other Liens on any Collateral for the Obligations.  The Credit Agreement and this Amendment shall be read and construed as one agreement.  Agent and Lenders hereby notify the Credit Parties that, effective from and after the date of this Amendment, Agent, and Lenders intend to enforce all of the provisions of the Loan Documents and that Agent and Lenders expect that the Credit Parties will strictly comply with the terms of the Loan Documents from and after this date.
7.2    Costs and Expenses.  The Credit Parties absolutely and unconditionally agree to pay to Agent, on demand by Agent at any time and as often as the occasion therefore may require, all reasonable and documented fees and out-of-pocket disbursements of any counsel to Agent in connection with the preparation, negotiation, execution, or delivery of this Amendment and any agreements delivered in connection herewith and reasonable expenses which shall at any time be incurred or sustained by Agent or any participant of Agent or any of its respective directors, officers, employees or agents as a consequence of or in any way in connection with the preparation, negotiation, execution, or delivery of this Amendment and any agreements prepared, negotiated, executed or delivered in connection herewith.
7.3    Further Assurances.  The parties hereto shall execute and deliver such additional documents and take such additional action as may be necessary or reasonably desirable to effectuate the provisions and purposes of this Amendment.
7.4    Binding Effect.  This Amendment shall be binding upon and inure to the benefit of each of the parties hereto and their respective successors and assigns.
7.5    Survival of Representations and Warranties.  All representations and warranties made in this Amendment or any other document furnished in connection with this Amendment shall survive the execution and delivery of this Amendment and the other documents, and no investigation by Agent or any Lender shall affect the representations and warranties or the right of Agent or the Lenders to rely upon them.
7.6    Releases by Credit Parties.  As a material inducement to Agent and the Lenders to enter into this Amendment and to grant concessions to the Credit Parties, all in accordance with and subject to the terms and conditions of this Amendment, each Credit Party:
(a)    Does hereby remise, release, acquit, satisfy and forever discharge Agent and the Lenders and their subsidiaries and affiliates, and all of their respective past, present and future officers, directors, employees, agents, attorneys, representatives, participants, heirs, successors and assigns (each a “Releasee” and collectively, the “Releasees”) from any and all manner of debts, accountings, bonds, warranties, representations, covenants, promises, contracts, controversies, arguments, liabilities, obligations, expenses, damages, judgments, executions, actions, claims, demands and causes of action of any nature whatsoever, whether at law or in equity, either now accrued or hereafter maturing or whether known or unknown, which any Credit Party now has or hereafter can, shall or may have by reason of any manner, cause or things, from the beginning of the world to and including the date of this Amendment, with respect to matters arising out of, in connection with or related to:

-5-
82932789_5

(i)    any and all obligations owed or owing to any Releasee under any document evidencing financial arrangements by, among and between such Releasee and any Credit Party, relating to the Credit Agreement, and including, but not limited to, the administration or funding thereof;
(ii)    the Credit Agreement and indebtedness evidenced and secured thereby; or
(iii)    any other agreement or transaction between any Credit Party and any Releasee entered into in connection with the Credit Agreement.
(b)    Does hereby covenant and agree never to institute or cause to be instituted or continued prosecution of any suit or other form of action or proceeding of any kind or nature whatsoever against any Releasee by reason of or in connection with any of the foregoing matters, claims or causes of action; provided, however, that the foregoing release and covenant not to sue shall not apply to any claim arising after the date of this Amendment with respect to acts, occurrences or events after the date of this Amendment; and, further provided that the foregoing release and covenant not to sue shall not apply to any rights or claims, if any, of any third party creditors of any Credit Party.  If any Credit Party or any of its successors, assigns or designees violates the foregoing covenant, such Credit Party and its successors, assigns and designees, jointly and severally agree to pay, in addition to such other damages as any Releasee may sustain as a result of such violation, all attorneys’ fees and costs incurred by any Releasee as a result of such violation.
(c)    Does hereby expressly acknowledge and agree that the covenants and agreements of Agent and the Lenders contained in this Amendment shall not be construed as an admission of any wrongdoing, liability or culpability on the part of Agent or any Lender or as any admission by Agent or any Lender of the existence of claims by any Credit Party against Agent, the Lenders or any other Releasee.  Each Credit Party, Agent and the Lenders acknowledge and agree that the value to the Credit Parties of the covenants, consents and agreements on the part of Agent and the Lenders contained in this Amendment substantially and materially exceed any and all value of any kind or nature whatsoever of any claims or other liabilities waived or released by the Credit Parties.
(d)    Notwithstanding anything contained in this Amendment, the general release set forth in this Amendment shall not extend to and shall not include any duties or obligations of Agent or the Lenders in the Credit Agreement as modified by this Amendment or in any of the Loan Documents.
7.7    Entire Agreement.  This Amendment (together with the Loan Documents) expresses the entire understanding and agreement of the parties hereto with respect to the subject matter hereof and supersedes all prior understandings, negotiations, correspondence and agreements of the parties regarding such subject matter.
7.8    GOVERNING LAW.  THE LAWS OF THE STATE OF NEW YORK SHALL GOVERN ALL MATTERS ARISING OUT OF, IN CONNECTION WITH OR RELATING TO THIS AMENDMENT, INCLUDING, ITS VALIDITY, INTERPRETATION, CONSTRUCTION, PERFORMANCE AND ENFORCEMENT (INCLUDING, ANY CLAIMS SOUNDING IN CONTRACT OR TORT LAW ARISING OUT OF THE SUBJECT MATTER HEREOF AND ANY DETERMINATIONS WITH RESPECT TO POST-JUDGMENT INTEREST).   
7.9    Incorporation of Credit Agreement Provisions.  The provisions contained in Sections 9.13, 9.14, 9.16, 9.18(b), 9.18(c), 9.18(d), 9.19, 9.23, and 9.24 of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety.  

-6-
82932789_5

7.10    Counterparts.  This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.  Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.  Delivery of an executed signature page of this Amendment by facsimile transmission or Electronic Transmission shall be as effective as delivery of a manually executed counterpart hereof.
[Signature Pages to Follow]

-7-
82932789_5

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by their respective duly authorized officers, as of the date first above written.

                    
HEALTHCARE FINANCIAL SOLUTIONS, LLC (as the successor in interest to GENERAL ELECTRIC CAPITAL CORPORATION),
as Administrative Agent, a Lender, and Swingline Lender

            
By:     /s/ R. Hanes Whiteley                
Name:     R. Hanes Whiteley 
Title:  Duly Authorized Signatory

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE 

OTHER LENDERS:

LEGACYTEXAS BANK

		
	By: 
	/s/ Lindsey Burris            

		
	Name: 
	Lindsey Burris                

		
	Title: 
	AVP, Corporate Healthcare Banking    

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE

BORROWER:  

NORTHSTAR HEALTHCARE 
ACQUISITIONS, L.L.C.

		
	By: 
	/s/ Matthew K. Maruca            

		
	Name: 
	Matthew K. Maruca            

		
	Title: 
	General Counsel            

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE 

CREDIT PARTIES:
NORTHSTAR HEALTHCARE HOLDINGS, INC. 
 
By: __/s/ Matthew K. Maruca__________________      
Name: _Matthew K. Maruca__________________
Title:     __General Counsel___________________
NOBILIS HEALTH CORP. 
 
By: __/s/ Matthew K. Maruca_________________      
Name:  Matthew K. Maruca___________________
Title:     General Counsel______________________

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE 

NORTHSTAR HEALTHCARE NORTHWEST HOUSTON MANAGEMENT, LLC 

By: Northstar Healthcare Acquisitions, L.L.C., its sole manager 
 
By:_/s/ Matthew K. Maruca_____________      
Name: Matthew K. Maruca______________
Title:     _General Counsel_______________
NORTHSTAR HEALTHCARE MANAGEMENT COMPANY, LLC 

By: Northstar Healthcare Acquisitions, L.L.C., its sole member 
 
By:__/s/ Matthew K. Maruca____________      
Name: _Matthew K. Maruca______________
Title:     _General Counsel________________
NORTHSTAR HEALTHCARE SURGERY CENTER – HOUSTON, LLC 

By: Northstar Healthcare Acquisitions, L.L.C., its sole member 
 
By:__/s/ Matthew K. Maruca____________      
Name: _Matthew K. Maruca____________
Title:     __General Counsel______________
NORTHSTAR HEALTHCARE SURGERY CENTER – SCOTTSDALE, LLC

By: Northstar Healthcare Acquisitions, L.L.C., its sole manager 
 
By:__/s/ Matthew K. Maruca_____________      
Name: _Matthew K. Maruca______________
Title:     __General Counsel_______________
NORTHSTAR HEALTHCARE SUBCO, L.L.C. 
 
By: __/s/ Matthew K. Maruca____________________      
Name: ___Matthew K. Maruca___________________
Title:     __General Counsel______________________

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE

NORTHSTAR HEALTHCARE LIMITED PARTNER, L.L.C. 
 
By: ___/s/ Matthew K. Maruca_____________      
Name: ___Matthew K. Maruca_____________
Title:     __General Counsel________________
NORTHSTAR HEALTHCARE GENERAL PARTNER, L.L.C. 
 
By: _____/s/ Matthew K. Maruca_____________      
Name: __Matthew K. Maruca________________
Title:     __General Counsel___________________
THE PALLADIUM FOR SURGERY – DALLAS, LTD. 

By: Northstar Healthcare General Partner, L.L.C., its sole general partner 
 
By:__/s/ Matthew K. Maruca____________      
Name: _Matthew K. Maruca_____________
Title:     General Counsel_________________
ATHAS HEALTH LLC 

By: Northstar Healthcare Subco, L.L.C., its sole member 
 
By: __/s/ Matthew K. Maruca_____________      
Name: _Matthew K. Maruca______________
Title:     _General Counsel________________
ATHAS ADMINISTRATIVE LLC 

By: Athas Health LLC, its sole member 
 
By: __/s/ Matthew K. Maruca_____________      
Name: _Matthew K. Maruca______________
Title:     _General Counsel_________________

ATHAS HOLDINGS LLC 

By: Athas Health LLC, its sole member 
 
By: _/s/ Matthew K. Maruca_______________      
Name: Matthew Maruca__________________
Title:     _General Counsel_________________

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE

FIRST NOBILIS HOSPITAL MANAGEMENT, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

NOBILIS HEALTH MARKETING, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

PEAK SURGEON INNOVATIONS, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

PEAK NEUROMONITORING ASSOCIATES – TEXAS II, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

NOBILIS SURGICAL ASSIST, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

SOUTHWEST HOUSTON SURGICAL ASSIST, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

SOUTHWEST FREEWAY SURGERY CENTER, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE

CENTRAL MEDICAL SOLUTIONS LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

PERIMETER ROAD SURGICAL HOSPITAL, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:      Matthew K. Maruca             
Title:     General Counsel            

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGE

HERMANN DRIVE SURGICAL HOSPITAL, LP 

By: Northstar Healthcare General Partner, L.L.C., its sole general partner 
 
By:__/s/ Matthew K. Maruca_____________      
Name: Matthew K. Maruca______________
Title: _General Counsel__________________
KUYKENDAHL ROAD SURGICAL HOSPITAL, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

PREMIER HEALTH SPECIALISTS, LLC 
 
By:    /s/ Matthew K. Maruca             
Name:     Matthew K. Maruca             
Title:     General Counsel            

CONCERTIS, LLC 
 
By:    /s/ Matthew K. Maruca         
Name:     Matthew K. Maruca             
Title:     General Counsel            

MARSH LANE SURGICAL HOSPITAL, LLC 
 
By:    /s/ Matthew K. Maruca         
Name:     Matthew K. Maruca             
Title:     General Counsel            

MPDSC, LLC  
 
By:    /s/ Matthew K. Maruca         
Name:     Matthew K. Maruca             
Title:     General Counsel            

NORTHSTAR HEALTHCARE ACQUISITIONS, L.L.C.
EIGHTH AMENDMENT TO CREDIT AGREEMENT AND LIMITED WAIVER
SIGNATURE PAGEExhibit

Exhibit 10.1

LAM RESEARCH CORPORATION  
2015 Stock Incentive Plan
Market-Based Performance Restricted Stock Unit Award Agreement
(U.S. Participants)

Pursuant to the terms of the 2015 Stock Incentive Plan (the “Plan”) Lam Research Corporation, a Delaware corporation (the “Company”), hereby awardsmarket-based performance restricted stock units (“mPRSUs”) to the Grantee (the “Participant”) on the terms and conditions as set forth in this Market-Based Performance Restricted Stock Unit Award Agreement (including the attached Exhibit A) (the “Agreement”) and the Plan.  Capitalized terms used but not defined in this Agreement shall have the meaning specified in the Plan.  This Agreement is effective as of the Grant Date.
NOW, THEREFORE, it is hereby agreed as follows:
1.Award of mPRSUs.  Subject to the terms and conditions of this Agreement and the Plan (the terms of which are incorporated herein by reference) and effective as of the date set forth above, the Company hereby grants to the Participant a Target Number of mPRSUs as set forth in Exhibit A.  Subject to the Company’s attainment of the relative performance set forth in the attached Exhibit A (the “Performance Criteria”), the Participant may vest in the mPRSUs in a designated Payout Range as set forth in Exhibit A.  The mPRSUs represent an unfunded, unsecured promise by the Company to deliver Shares subject to the terms and conditions of this Agreement.  
2.    Vesting.
(a)     Subject to the terms and conditions of this Agreement, the mPRSUs shall vest and become payable in Shares on the Performance Vesting Date set forth in the attached Exhibit A.  The number of mPRSUs that vest shall be determined by the Company’s performance under the Vesting Formula during the Performance Period, as set forth in the attached Exhibit A.  Except as otherwise provided herein, the Participant’s right to receive Shares subject to the mPRSUs is contingent upon the Participant continuing to provide Service (as defined in Section 3 below) to the Company (or any Related Entity) through the Performance Vesting Date.
(b)    Notwithstanding the provisions above, in the event of a Corporate Transaction prior to the end of the Performance Period in Section 2(a), a portion of the mPRSUs shall convert into a cash award (the “Cash Award”).  The number of mPRSUs that convert into a Cash Award shall be the sum of the “performance pro rata” number of Shares and the “target pro rata” number of Shares.  This sum shall be multiplied by the closing price of the Company’s common stock as of the closing date of the Corporate Transaction to determine the dollar amount of the Cash Award.  The Cash Award will vest on the Performance Vesting Date, contingent upon the Participant continuing to provide Service (as defined in Section 3 below) to the Company (or any Related Entity) through the Performance Vesting Date.  Any remaining portion of the mPRSUs that are not converted into a Cash Award shall be cancelled.

Page 1 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

(i)     Performance Pro Rata.  The Target Number of mPRSUs (as set forth in the attached Exhibit A) shall be multiplied by the total number of days from the first day of the Performance Period until the closing date of the Change in Control divided by the number of days in the Performance Period (“Elapsed Target Shares”).  The Company’s performance under the Vesting Formula (as set forth in the attached Exhibit A) from the first day of the Performance Period until the closing date of the Corporate Transaction shall be applied to the Elapsed Target Shares to determine the “performance pro rata” number of Shares.
(ii)    Target Pro Rata.  The Target Number of mPRSUs (as set forth in the attached Exhibit A) shall be multiplied by the total number of days from the day following the closing date of the Corporate Transaction until the last day of the Performance Period divided by the number of days in the Performance Period to determine the “target pro rata” number of Shares.   
3.    Effect of Termination of Service or Leave of Absence.
(a)    For purposes of this Agreement, “Service” shall mean the performance of services for the Company (or any Related Entity) in the capacity of an Employee and shall be considered terminated on the last day the Participant is on payroll.  In the event of termination of the Participant’s Service by the Participant or by the Company or a Related Entity for any reason, excluding Participant’s death or Disability before the mPRSUs have vested, the unvested mPRSUs shall be cancelled by the Company (subject to the terms of any applicable Employment or Change in Control Agreement).  
(b)    In the event of termination of the Participant’s Service due to death, a portion of the mPRSUs granted to the Participant shall vest on the date of death.  To determine the applicable number of Shares, the Target Number of mPRSUs (as set forth in the attached Exhibit A) shall be multiplied by the total number of days from the first day of the Performance Period until the date of death, divided by the number of days in the Performance Period to determine the “death pro rata” target number of Shares.  The Company’s performance under the Vesting Formula (as set forth in the attached Exhibit A) from the first day of the Performance Period until the date of death shall be applied to the greater of: (i) the “death pro rata” target number of Shares or (ii) 50% of the original Target Number of mPRSUs (as set forth in the attached Exhibit A), to determine the number of Shares which shall vest on the date of death (the “Death Vesting Date”).  Any remaining unvested portion of the mPRSUs shall be cancelled.
(c)    In the event of termination of the Participant’s Service due to Disability, a portion of the mPRSUs granted to the Participant shall vest on the date the Disability is incurred.  To determine the applicable number of Shares, the Target Number of mPRSUs (as set forth in the attached Exhibit A) shall be multiplied by the total number of days from the first day of the Performance Period until the date the Disability is incurred, divided by the number of days in the Performance Period to determine the “disability pro rata” target number of Shares.  The Company’s performance under the Vesting Formula (as set forth in the attached Exhibit A) from the first day of the Performance Period until the date the Disability is incurred shall be applied to the greater of: (i) the “disability pro rata” target number of Shares or (ii) 50% of the original Target Number of mPRSUs (as set forth in the attached Exhibit A) to determine the number of 

Page 2 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

Shares which shall vest on the date the Disability is incurred (the “Disability Vesting Date”, and collectively with “Performance Vesting Date”, and the “Death Vesting Date”, the “Vesting Date”).  Any remaining unvested portion of the mPRSUs shall be cancelled.
(d)    Vesting of the mPRSUs will be suspended and vesting credit will no longer accrue as of the day of the Leave of Absence as set forth in Exhibit A, unless otherwise determined by the Administrator or required by contract or statute.  If the Participant returns to Service immediately after the end of an approved Leave of Absence, vesting credit shall continue to accrue from that date of continued Service.

4.    Form and Timing of Payment.  
(a)    Subject to Section 5 of this Agreement and provided that the Participant has satisfied the vesting requirements of Section 2 or 3 of this Agreement, on each Vesting Date, as applicable, the mPRSUs shall automatically be converted into unrestricted Shares.  Such Shares will be issued to the Participant (as evidenced by the appropriate entry in the books of the Company or a duly authorized transfer agent of the Company) on the applicable Vesting Date (or as soon as practicable), but in any event, within the period ending on the later to occur of the date that is 2 1⁄2 months after the end of (i) the Participant’s tax year that includes the applicable Vesting Date, or (ii) the Company’s tax year that includes the applicable Vesting Date.  
(b)    Shares issued in respect of mPRSUs shall be deemed to be issued in consideration of past services actually rendered by the Participant to the Company or a Related Entity or for its benefit for which the Participant has not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value of the Shares subject to the mPRSUs. 
5.    Tax Withholding Obligations.  Regardless of any action the Company or the Participant’s employer (the “Employer”) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, or other tax-related withholding (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items legally due by the Participant is and remains the Participant’s responsibility and that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the mPRSUs, including the grant of the mPRSUs, the vesting of the mPRSUs, or the receipt of an equivalent cash payment, the subsequent sale of any Shares acquired at vesting and the receipt of any dividends; and (ii) do not commit to structure the terms of the grant or any aspect of the mPRSUs to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result.
Prior to the issuance of Shares upon vesting of the mPRSUs (or any other tax or withholding event), the Participant shall pay, or make arrangements satisfactory to the Company (in the Company’s sole discretion) to satisfy all withholding obligations.  In those cases where a prior arrangement has not been made (or where the amount of money provided under the prior arrangement is insufficient to satisfy the obligations for Tax-Related Items), the Company shall withhold a number of whole Shares otherwise deliverable at vesting having a Fair Market Value sufficient to satisfy the statutory minimum (or such higher amount as is allowable without 

Page 3 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

adverse accounting consequences) of the Participant’s estimated obligations for Tax-Related Items applicable to the mPRSUs; such withholding will result in the issuance to the participant of a lower number of Shares.  
The Company and/or the Employer may also, in lieu of or in addition to the foregoing, at the Company’s sole discretion, as authorized herein by the Participant, withhold all applicable Tax-Related Items legally payable by the Participant from the Participant’s wages or other cash compensation or to withhold in one of the following ways, as determined by the Company: (i) require the Participant to deposit with the Company an amount of cash sufficient to meet his or her obligation for Tax-Related Items, and/or (ii) sell or arrange for the sale of Shares to be issued on the vesting of the mPRSUs to satisfy the withholding obligation.  If the Participant’s obligation for Tax-Related Items is satisfied as described in (ii) of this section, the Company will endeavor to sell only the number of Shares required to satisfy the Participant’s obligations for Tax-Related Items; however, the Participant agrees that the Company may sell more Shares than necessary to cover the Tax-Related Items and that in such event, the Company will reimburse the Participant for the excess amount withheld, in cash and without interest.  The Participant shall pay to the Employer any amount of Tax-Related Items that the Employer may be required to withhold as a result of the Participant’s receipt of the mPRSUs, the vesting of the mPRSUs that cannot be satisfied by the means previously described.  The Company may refuse to deliver Shares to the Participant if the Participant fails to comply with his or her obligation in connection with the Tax-Related Items as described herein.  The Participant hereby consents to any action reasonably taken by the Company and/or the Employer to meet his or her obligation for Tax-Related Items.
Further, in consideration of the grant of the mPRSUs, no claim or entitlement to compensation or damages arises if, in satisfying the Participant’s (and/or the Employer’s) obligation for Tax-Related Items, the Company and/or the Employer withholds an amount in excess of the amount legally required to be withheld, the Participant irrevocably releases the Company and the Employer from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing this Agreement, the Participant shall be deemed irrevocably to have waived his or her entitlement to pursue such claim or damages.
6.    Restriction on Transferability.  Prior to vesting and delivery of the Shares, neither the mPRSUs, nor the Shares or any beneficial interest therein, may be sold, transferred, pledged, assigned, or otherwise alienated at any time.  Any attempt to do so contrary to the provisions hereof shall be null and void.  Notwithstanding the above, distribution can be made pursuant to will, the laws of descent and distribution, and if provided by the Administrator, intra-family transfer instruments, or to an inter vivos trust, or as otherwise provided by the Administrator.  The terms of this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Participant.
7.    Requirements of Law.  The issuance of Shares upon vesting of the mPRSUs is subject to Sections 9 and 14(b) of the Plan, which generally provides that any such issuance shall be subject to compliance by the Company and the Participant with all applicable requirements of 

Page 4 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

law relating thereto and with all applicable regulations of any stock exchange on which the Shares may be listed for trading at the time of such issuance.  The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance of any Shares hereby shall relieve the Company of any liability with respect to the non-issuance of the Shares as to which such approval shall not have been obtained.  The Company, however, shall use its reasonable efforts to obtain all such approvals.
8.    Rights as Stockholder.  The Participant shall not have voting, dividend or any other rights as a stockholder of the Company with respect to the mPRSUs. Upon settlement of the Participant’s mPRSUs into Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), the Participant will obtain full voting, dividend and other rights as a stockholder of the Company.
9.    No Compensation Deferrals.  Neither the Plan nor this Agreement is intended to provide for an elective deferral of compensation that would be subject to Section 409A (“Section 409A”) of the Internal Revenue Code of 1986, as amended (the “Code”).  If, notwithstanding the parties’ intent in this regard, at the time of the Participant’s termination of Service, he or she is determined to be a “specified employee” as defined in Code Section 409A, and one or more of the payments or benefits received or to be received by the Participant pursuant to the mPRSUs would constitute deferred compensation subject to Code Section 409A, no such payment or benefit will be provided under the mPRSUs until the earliest of (A) the date which is six (6) months after the Participant’s “separation from service” for any reason, other than death or “disability” (as such terms are used in Section 409A(a)(2) of the Code), (B) the date of the Participant’s death or “disability” (as such term is used in Section 409A(a)(2)(C) of the Code), or (C) the effective date of a “change in the ownership or effective control” or a “change in ownership of a substantial portion of the assets” of the Company (as such terms are used in Section 409A(a)(2)(A)(v) of the Code). The provisions of this Section 9 shall only apply to the extent required to avoid the Participant’s incurrence of any additional tax or interest under Code Section 409A or any regulations or U.S. Department of the Treasury (“Treasury”) guidance promulgated thereunder.  In addition, if any provision of the mPRSUs would cause the Participant to incur any additional tax or interest under Code Section 409A or any regulations or Treasury guidance promulgated thereunder, the Company reserves the right, to the extent the Company deems necessary or advisable in its sole discretion, to unilaterally amend or modify the Plan and/or this Agreement to conform it to the maximum extent practicable to the original intent of the applicable provision without violating the provisions of Code Section 409A, including without limitation to limit payment or distribution of any amount of benefit hereunder in connection with a Corporate Transaction to a transaction meeting the definitions referred to in clause (C) above, or in connection with any disability to a “disability” as referred to in (B) above; provided however that the Company makes no representation that these Performance Restricted Stock Units are not subject to Section 409A nor makes any undertaking to preclude Section 409A from applying to these mPRSUs.  In addition, to the extent the Company determines it appropriate to accelerate any vesting conditions applicable to this award, then to the extent necessary to avoid the Participant’s incurring any additional tax or interest as a result of such vesting acceleration under Code Section 409A or any regulations or Treasury guidance promulgated thereunder, and notwithstanding Section 4 above, the Company may as a condition 

Page 5 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

to extending such acceleration benefits provide for the Shares to be issued upon settlement of the mPRSUs to be issued on the earliest date (the “Permitted Distribution Date”) that would obviate application of such additional tax or interest rather than issuing them upon the date on which such vesting is effective as would otherwise be required under Section 2 (or as soon as practicable after such Permitted Distribution Date and in no event later than that last day of the grace period following such date permitted under Code Section 409A).  
10.    Administration.  The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation, and application of the Plan as are consistent therewith and to interpret or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator shall be final and binding upon the Participant, the Company, and all other interested persons.  No Administrator shall be personally liable for any action, determination, or interpretation made in good faith with respect to the Plan or this Agreement.
11.    Effect on Other Employee Benefit Plans.  The value of the mPRSUs granted pursuant to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the Participant’s benefits under any employee benefit plan sponsored by the Company or any Related Entity, except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Related Entity’s employee benefit plans.
12.    No Employment Rights.  The award of the mPRSUs pursuant to this Agreement shall not give the Participant any right to continued Service with the Company or a Related Entity and shall not interfere with the ability of the Employer to terminate the Participant’s Service with the Company at any time with or without cause.
13.    Nature of the Grant.  In accepting the mPRSUs, the Participant acknowledges that: 
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement; 
(b)the grant of mPRSUs is voluntary and occasional and does not create any contractual or other right to receive future awards of mPRSUs, or benefits in lieu of mPRSUs even if mPRSUs have been awarded repeatedly in the past; 
(c)all decisions with respect to future grants of mPRSUs, if any, will be at the sole discretion of the Company; 
(d)the Participant’s participation in the Plan is voluntary; 
(e)the mPRSUs are outside the scope of the Participant’s employment contract, if any; 

Page 6 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

(f)the mPRSUs are not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculation of any overtime, severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(g)in the event that the Participant is not an employee of the Company, the grant of the mPRSUs will not be interpreted to form an employment contract or relationship with the Company; and furthermore, the grant of the mPRSUs will not be interpreted to form an employment contract with the Employer or any Related Entity; 
(h)the future value of the underlying Shares is unknown and cannot be predicted with certainty; 
(i)if the Participant receives Shares upon vesting of the mPRSUs, the value of such Shares may increase or decrease in value; 
(j)in consideration of the grant of the mPRSUs, no claim or entitlement to compensation or damages arises from termination of the mPRSUs or diminution in value of the mPRSUs or Shares received upon vesting of mPRSUs resulting from termination of the Participant’s Service to the Company or the Employer (for any reason whatsoever and whether or not in breach of local labor laws) and the Participant irrevocably releases the Company and the Employer from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing this Agreement, the Participant shall be deemed irrevocably to have waived his or her entitlement to pursue such claim. 
14.    Amendment of Agreement.  This Agreement may be amended only by a writing which specifically states that it amends this Agreement. Notwithstanding the foregoing, this Agreement may be amended unilaterally by the Committee by a writing which specifically states that it is amending this Agreement, so long as a copy of such amendment is delivered to the Participant, and provided that no such amendment adversely affects the rights of the Participant.  Limiting the foregoing, the Committee reserves the right to change, by written notice to the Participant, the provisions of the mPRSUs or this Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, or, to the extent permissible under the Plan (including, but not limited to, Sections 10, 11 and 13 of the Plan).  
15.    Notices.  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Stock Administrator. Any notice to be given to the Participant shall be addressed to the Participant at the address listed in the Employer’s records.  By a notice given pursuant to this Section, either party may designate a different address for notices.  Any notice shall have been deemed given when actually delivered.
16.    Severability.  The provisions of this Agreement are severable and if all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or 

Page 7 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.
17.    Construction.  The mPRSUs are being issued pursuant to the Plan and are subject to the terms of the Plan. A copy of the Plan is available upon request during normal business hours at the principal executive offices of the Company.  To the extent that any provision of this Agreement violates or is inconsistent with a provision of the Plan, the Plan provision shall govern and any inconsistent provision in this Agreement shall be of no force or effect.
18.    Electronic Delivery.  The Company may, in its sole discretion, decide to deliver any documents related to the mPRSUs granted under the Plan and participation in the Plan or future mPRSUs that may be granted under the Plan by electronic means or to request the Participant’s consent to participate in the Plan by electronic means.  The Participant hereby consents to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.
19.    Entire Agreement.  The Plan is incorporated herein by reference.  The Plan and this Agreement constitute the entire agreement of the Company and the Participant with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof.
20.    Miscellaneous.
(a)    The Company has established the Plan voluntarily, it is discretionary in nature and the Board may terminate, amend, or modify the Plan at any time; provided, however, that no such termination, amendment, or modification of the Plan may in any way adversely affect the Participant’s rights under this Agreement, without the Participant’s written approval unless such termination, amendment, or modification of the Plan is necessary in order to comply with any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision or as otherwise permissible under the Plan (including, but not limited to, Sections 10, 11 and 13 of the Plan).
(b)    All obligations of the Company under the Plan and this Agreement in a Corporate Transaction shall be governed by the Plan and this Agreement, other than as set forth in Section 3(a) above.
(c)    By signing this Agreement, the Participant acknowledges that his or her personal employment or Service information regarding participation in the Plan and information necessary to determine and pay, if applicable, benefits under the Plan must be shared with other entities, including companies related to the Company and persons responsible for certain acts in the administration of the Plan.  By signing this Agreement, the Participant consents to such transmission of personal data as the Company believes is appropriate to administer the Plan.

Page 8 
Version 2 (Aug 2016)

2015 Stock Incentive Plan Market-Based Performance Restricted Stock Unit Award Agreement for U.S. Participants

(d)    To the extent not preempted by federal law, this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to its principles of conflict of laws.
21.    Acceptance of Terms and Conditions.  By accepting the terms and conditions of this Agreement, the Participant agrees to abide by all of the governing terms and provisions of the Plan and this Agreement.  Additionally, the Participant acknowledges having read and understood the terms and conditions of the Plan and this Agreement and has had an opportunity to obtain the advice of counsel prior to accepting this Agreement.  The Participant must acknowledge his or her agreement to abide by the terms and conditions of the Plan and Agreement by executing this Agreement electronically or, if otherwise instructed by the Company, by printing and signing a paper copy of this Agreement and returning it to the appropriate Company representative.  In addition, the transfer or sale of the shares obtained at vesting by the Participant shall be considered an additional acknowledgment of the terms and conditions contained in the Plan and Agreement.  

*    *    *   *   *
	
		
	PARTICIPANT SIGNATURE
	[Electronic Signature]

	PRINTED NAME
	[Participant Name]

	DATE   
	[Acceptance Date]

    

Page 9 
Version 2 (Aug 2016)

LAM RESEARCH CORPORATION
2015 Stock Incentive Plan 
Market-Based Performance Restricted Stock Unit Award Agreement
EXHIBIT A
([___________] Vesting)

Participant (Name & Employee Number): 

Grant Date: 

Target Number of mPRSUs: 

Performance Vesting Date: 

Payout Range: 0% to 150% of Target Number of mPRSUs

Performance Period:                         to                                 .

Performance Criteria:

		
	•
	Index 

PHLX Semiconductor Sector Index, a global index traded on the NASDAQ OMX PHLX with a trading symbol of “SOX”

		
	•
	Vesting Formula

Target Number of mPRSUs x (100% + ((LRCX TSR % – Index TSR %) x 2)) = mPRSUs vested (subject to the maximum in the Payout Range)

		
	◦
	Target Number of mPRSUs is vested if the LRCX TSR % equals the Index TSR %

		
	◦
	Number of mPRSUs vested increases by 2% of target for each 1% that the LRCX TSR % exceeds the Index TSR %

		
	◦
	Number of mPRSUs vested decreases by 2% of target for each 1% that the LRCX TSR % trails the Index TSR %

		
	◦
	The result of the Vesting Formula is rounded down to the nearest whole number

		
	•
	LRCX TSR %

(LRCX 50-trading day average closing price as of the last trading day of the Performance Period – LRCX 50-trading day average closing price on the trading day immediately prior to the beginning of the Performance Period) ÷ (LRCX 50-trading day average closing price on the trading day immediately prior to the beginning of the Performance Period) x 100

		
	•
	Index TSR %

Exhibit A – Market-Based Performance Restricted Stock Unit Award Agreement

(Index 50-trading day average closing price as of the last trading day of the Performance Period – Index 50-trading day average closing price on the trading day immediately prior to the beginning of the Performance Period) ÷ (Index 50-trading day average closing price on the trading day immediately prior to the beginning of the Performance Period) x 100

		
	•
	Notes: 

		
	▪
	The LRCX TSR % calculation excludes any dividends paid on the Company’s common stock. 

		
	▪
	All Index TSR % calculations are based on the companies traded on the Index as of the applicable dates

		
	o
	E.g., The Index is used as of the applicable dates even if companies are added / removed from the Index during the Performance Period.

		
	▪
	The Company’s relative performance is determined using calculations based on the 50-trading day average closing price methodology for all TSR calculations.

		
	▪
	In the event of a Corporate Transaction, the closing price of the Company’s common stock as of the closing date of the Corporate Transaction is used to convert the sum of the “performance pro rata” and “target pro rata” number of Shares into the Cash Award.

		
	▪
	If the Index is no longer traded / calculated, the Company’s relative performance is determined using calculations based on the companies included in the Index at the time trading / calculation last occurred.  The Compensation Committee will calculate the Index TSR % in the manner that most closely approximates the Index in its sole discretion.

Leave of Absence:  31st day (or 91st day if reemployment guaranteed by statute or contract)

Version 1 (Nov 2015)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]